Lexicon Pharma (LXRX) reported earnings on Wed 13 March 19 (b/o)

 

Lexicon Pharma beats by $0.12, beats on revs

• Reports Q4 (Dec) loss of $0.16 per share, $0.12 better than the S&P Capital IQ Consensus of ($0.28); revenues fell 49.7% year/year to $17.1 mln vs the $13.33 mln S&P Capital IQ Consensus.
• Anticipated Upcoming Milestones
  • Q1 2019 -- Manuscript publications for XERMELO in carcinoid syndrome diarrhea
  • Q1 2019 -- Initiation of a Phase 1b study for LX9211
  • March 22, 2019 -- PDUFA date for sotagliflozin in type 1 diabetes in the U.S.
  • Q2 2019 -- European Commission decision on marketing application for sotagliflozin in type 1 diabetes in the EU